MultiCell Technologies, Inc. (MCET)
(U.S. Reporting: SEC Filer)
Outstanding shares 5,000,948,700 as of Jul 8, 2015
Office: (401) 762-0045 | Email: email@example.com
(This "Intro Box" is NOT maintained by MultiCell Technologies and is intended solely as a quick information source on ihub. For more detailed, up-to-date information on MultiCell Technologies, please go the company website.)
MultiCell inks R&D agreement with Oxis Biotech
MultiCell Technologies (OTCPK: MCET) subsidiary MultiCell Immunotherapeutics enters into a research and development and product license agreement with Oxis Biotech (OTCQB: OXIS) to create three novel antibody-drug conjugates (ADCs) based on Oxis' lead drug candidates and MultiCell's proprietary ADC platform technology. The ADCs will be targeted for the treatment of triple-negative breast cancer and multiple myeloma and associated osteolytic lesions.
Under the terms of the agreement, Oxis will pay MultiCell a license fee of $500K, up to $12.75M in clinical development milestones and a royalty of 3% on net sales. Oxis will also reimburse MultiCell up to $1.125M in development costs. MultiCell grants Oxis an option to purchase manufacturing rights to the three ADCs upon the payment of an additional $10M.
MultiCell retains all rights to its ADC platform for all indications and is free to pursue its own drug development programs and to partner with other firms.
MultiCell Technologies’ portfolio of lead drug candidates is in various stages of preclinical and clinical development:
MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.
MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.
MCT-475, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.
MCT-485, a discovery stage dsRNA therapeutic candidate for the treatment of certain cancers.
| Indication || |
| || || || || |
| || || || || |
| || || || || |
| || || || || |
Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.
MultiCell Technologies, Inc. Corporate Headquarters
68 Cumberland Street, Suite 301
Woonsocket, RI 02895
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.
Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.
Our most advanced lead drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.
While significant progress has been made in developing cancer therapies that result in tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. MultiCell is also developing novel therapeutics for the treatment of cancer. MCT-465, MCT-475 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented therapeutic antibody and synthetic dsRNA technologies. MCT-465, a potent immune enhancer, is indicated as an cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be used with our MCT-475 antibody therapeutic for the treatment of various cancers such as breast carcinoma. MCT-485, a cytotoxic agent, is a novel synthetic dsRNA with therapeutic properties distinct from those of MCT-465, and is indicated for the treatment of certain cancers. MCT-465 is in early-stage preclinical development, and MCT-475 and MCT-485 are in the discovery optimization stage of development.
The role liver stem cells play in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. MultiCell is developing therapeutic product opportunities specifically targeting the treatment of hepatocellular carcinoma and intrahepatic bile duct cancer by leveraging our synthetic dsRNA and antibody therapeutic platforms against cancer stem cells. MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), and several corresponding issued and pending patents and patent applications related to the isolation and differentation of liver stem cells.
Find us on Google Maps http://www.facebook.com/MCET.OB
Management and Board of Directors
Barbara (Corbett) Newmin - Investor Relations
W. Gerald Newmin, Chairman and Chief Executive Officer
Dr. Steve Chang Ph. D., Director
Grant Miller, Director
Alan Tuchman, M.D.
Thomas A. Page, Director
Edward Sigmond, Director